** Women using their own eggs at Genea clinics excluding Christchurch, Perth and Newcastle (Feb 2016-Dec 2016). Miscarriage calculated as loss between foetal heart pregnancy and live birth.
Chat with our Fertility Advisor

Genea Fertility has legal obligations to protect your personal information and to provide you with details about how we deal with this information. Please read our Privacy Policy and Collection Statement.



PGD is used by couples who know they carry a serious genetic disorder, a genetic work-up is required and the embryos are tested for a specific abnormality. PGS is a full review of chromosome number and order and is used by couples who have experienced recurrent miscarriage, numerous failed embryo transfers and/or older patients. 

Embryos develop in the laboratory for five days until they reach what is called the blastocyst stage, before a biopsy is performed to remove a small number of cells for PGD/PGS screening.

Genea’s GeneSure™ technology uses preimplantation genetic screening to detect chromosomal abnormalities to select the best possible embryo for transfer - as a result of the technology, at Genea, we have seen a 50% decrease in miscarriage rate* and double the live birth rates*

* Per embryo transfer. Compared to standard IVF for women 38 years and over where the embryos are not tested for chromosomal abnormalities.

At Genea, we have experience with more than 350 genetic diseases as part of our PGD program so far. For example: Duchenne muscular dystrophy, Huntington disease, Leigh’s disease, Fragile X and cystic fibrosis. 

Genea has pioneered pre-implantation genetic testing, our expertise and techniques are amongst the best in the world. Many clinics have followed our lead and modelled their approach to embryo biopsy on ours. Genea is one of the very few clinics in Australia with the vital combination of IVF and genetics facilities to perform these sophisticated genetic screening tests successfully.